Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04925674
Other study ID # HEC53856-RAD-103
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date September 29, 2021
Est. completion date January 14, 2023

Study information

Verified date June 2021
Source Sunshine Lake Pharma Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of HEC53856 capsules on anemia in subjects with chronic kidney disease on dialysis.


Description:

The purpose of this multicenter, open-label, dose-increasing, multiple-dose study was to evaluate the safety, tolerability,PK and preliminary efficacy of HEC53856 capsules in renal anemia subjects on dialysis. The study consists of two parts, hemodialysis or peritoneal dialysis . Within each part participants will be administrated for HEC53856. There are three study periods: Screening period :up to 2weeks; Treatment period: 6 weeks(except that 7 weeks in the 100mg cohort in the hemodialysis); Follow-up period: 2weeks.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date January 14, 2023
Est. primary completion date September 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. The subject voluntarily participated in this clinical trial and signed an informed consent form; 2. 18-70 years old, weight 45~90kg, including cut-off value; 3. Hemodialysis (Hemodialysis, HD): Patients with end-stage renal disease who are on stable dialysis receive 3 times a week hemodialysis for at least 3 months before screening, and can receive 3 times a week hemodialysis at regular intervals during the test. The duration of the subject's hemodialysis treatment must be 3-4.5 hours (including the cut-off value); Peritoneal dialysis: For patients with end-stage renal disease on stable dialysis, the subject must receive peritoneal dialysis for at least 3 months before screening; 4. Subjects stop EPO 14 days or 5 half-lives (whichever is the longest) before taking the test drug for the first time; 5. Subjects have stable dialysis methods and dialysis prescriptions, and are expected to have no major treatment changes or no drastic changes in their condition during the clinical trial period; 6. During the screening period, the hemoglobin value obtained by the two tests of Visit 1 and Visit 2 must be > or = 8.0 g/dL and <11.0 g/dL, and the difference between the two must be < or = 1.5 g/dL. Exclusion Criteria: 1. Existence of past medical history or conditions that may cause anemia other than nephropathy, including but not limited to blood system diseases, such as thalassemia, aplastic anemia, hemolytic anemia, multiple myeloma, myelodysplastic syndrome, etc.; Autoimmune diseases that may affect red blood cell production, such as systemic lupus erythematosus, rheumatoid arthritis, etc.; Bleeding diseases, such as gastrointestinal bleeding, obstetrics and gynecology bleeding diseases, etc. 2. During the study period, those who plan to change the dialysis method/mode or the flux of the hemodialysis machine, such as changing from peritoneal dialysis to hemodialysis 3. Those who have any of the following heart/cerebrovascular diseases: 1. Acute coronary syndrome, stroke (except lacunar infarction) or thromboembolic disease (such as deep vein thrombosis or pulmonary embolism) occurred within 6 months before screening; 2. Heart Function III of New York Society of Cardiology Or grade IV congestive heart failure, or severe arrhythmia, including but not limited to ventricular tachycardia, ventricular fibrillation, III degree atrioventricular block, etc. 4. Those who have any of the following medical or surgical history: 1. Those who plan to undergo major surgery 3 months before screening or during the study period (except for hemodialysis access repair) or blood transfusion therapy; 2. Have peritoneal dialysis related 3 months before screening Peritonitis, history of infection or leakage of peritoneal tube tunnel; 3. history of malignant tumor within 5 years prior to screening (except for cured skin basal cell carcinoma and cervical carcinoma in situ), or current assessment of potential malignant tumor; 4. suffering Uncontrollable or symptomatic secondary hyperparathyroidism, plasma iPTH>800pg/ml; 5. History of dysphagia or any gastrointestinal disease that affects drug absorption, history of gastric/jejunum/colon resection; f ) Those who have a serious infection and are receiving systemic antibiotic treatment; g) Anyone who has participated or plans to participate in an organ transplant within 6 months; h) Have a history of chronic liver disease (such as: chronic infectious hepatitis, chronic autoimmune liver disease, cirrhosis Or liver fibrosis); i) Patients with a history of polycystic kidney disease. 5. Any of the following laboratory abnormalities during the screening period: 1. Folic acid <6.8nmol/L (3ng/ml) and/or VitB12<74pmol/L (100ng/ml); 2. Serum albumin <3 g/dL; 3. AIDS antibody , Treponema pallidum antibody, hepatitis B surface antigen or hepatitis C antibody positive for any one; 4. ALT>3×ULN and/or AST>3×ULN, or total bilirubin>1.5× ULN; 6. Subjects received intravenous iron supplementation within 4 weeks before screening, or used Chinese patent medicines, androgens and anabolic hormone drugs, hypoxia-inducible factor prolyl hydroxylase for the treatment of anemia within 4 weeks before screening Inhibitors (such as Roxastat capsules) and other drugs (except ESAs and their derivatives, oral irons, stable oral irons can be taken within 4 weeks before the screening, and in the screening period and after the start of the trial drug Continue to take the fixed dose for 6 weeks.) 7. Subjects who are expected to take BCRP inhibitors, BCRP inducers, CYP2C8 inhibitors and inducers within 14 days before taking the test drug (or 5 half-lives of the drug, whichever is the longest) until the end of the drug; 8. Those who have a history of drug abuse or drug abuse within 6 months before screening; 9. The mean systolic blood pressure =180 mmHg and/or the diastolic blood pressure > or = 110 mmHg of two supine blood pressure measurements at least 1 hour apart during the screening period; 10. People with a history of severe allergic disease or drug allergy, or those who are allergic to test drugs or their excipients; 11. Those who drink more than 14 units per week in the 3 months before screening (1 unit of alcohol ˜ 360 mL of beer or 45 mL of spirits with 40% alcohol content or 150 mL of wine), or those who cannot abstain from alcohol during the hospitalization; 12. Those who smoked more than 10 cigarettes per day in the 3 months before screening, or who could not stop using any tobacco products during the hospitalization; 13. Women who have a positive pregnancy test or are breastfeeding, or men and women who refuse to take effective contraceptive measures within 4 weeks from the signing of the informed consent form to the end of the last trial drug administration; 14. Participated in other clinical trials within 3 months before screening (Definition of participation: accepted experimental drugs or instrument); 15. Subjects may not be able to complete all research visits or procedures required by the research protocol, and/or fail to comply with all required research procedures; 16. The investigator believes that there are other factors that are not suitable for participating in this trial;

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
HEC53856
The 100mg dose cohort in the hemodialysis: D1 single oral administration of the investigation product 2.5h before hemodialysis; Three times a week for 6 weeks starting from D8, oral administration of the test drug 2.5h after hemodialysis. The rest dose cohorts in the hemodialysis: Three times a week for 6 weeks starting from D1, oral administration of the investigation product 2.5h after hemodialysis. The dose cohort in the peritoneal dialysis: Three times a week for 6 weeks starting from D1, oral administration of the investigation product after fasting.

Locations

Country Name City State
China Sichuan Provincial People's Hospital Chengdu
China The First Affiliated Hospital, Sun Yat-sen University Guangzhou Guangdong
China The First Affiliated Hospital of Shantou University Medical College Shantou
China The First Hospital of China Medical University Shenyang
China General Hospital of Tianjin Medical University Tianjin
China Affiliated Hospital of Guangdong Medical University Zhanjiang
China The Fifth Affiliated Hospital Sun Yat-sen University Zhuhai

Sponsors (2)

Lead Sponsor Collaborator
Sunshine Lake Pharma Co., Ltd. Nicoya Therapeutics (Shanghai) Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Adverse Events To assess the safety and tolerability of therapy by incidence of treatment-emergent adverse events after multiple doses of HEC53856 capsule Up to 2 weeks after last dose
Secondary AUC0-t Area under the concentration versus time curve (AUC) from time zero to the time of the last quantifiable concentration Up to 72 hours after single and multiple drug dosing
Secondary Cmax Maximum observed plasma concentration Up to 72 hours after single and multiple drug dosing
Secondary Tmax Time of the maximum observed plasma concentration Up to 72 hours after single and multiple drug dosing
Secondary Apparent terminal elimination half-life Up to 72 hours after single and multiple drug dosing
Secondary Vz/F Apparent volume of distribution Up to 72 hours after single and multiple drug dosing
Secondary Changes in mean hemoglobin Changes in mean hemoglobin (Hb) relative to baseline during visit 8 and 9. Up to 2 weeks after the last dose
Secondary Hemoglobin response Percentage of subjects who met the hemoglobin response after dosing Up to 2 weeks after the last dose
Secondary E-AUC0-t Area under the EPO concentration versus time curve (AUC) from time zero to the time of the last quantifiable concentration Up to 72 hours after single and multiple drug dosing
Secondary Emax Maximum observed EPO concentration Up to 72 hours after single and multiple drug dosing
Secondary E-Tmax Time of the maximum observed EPO concentration Up to 72 hours after single and multiple drug dosing
Secondary Serum lipid Changes in Serum lipid relative to baseline at visit 8. week 6
Secondary Indicators of iron Changes in the Indicators of iron relative to baseline at visit 8 week 6
Secondary High-sensitivity C-reactive protein Changes in the High-sensitivity C-reactive protein relative to baseline at visit 8. week 6
Secondary Reticulocytes Changes in the mean Reticulocytes relative to baseline after doses. Up to week 8
Secondary VEGF Changes in the VEGF relative to baseline after doses. week 6
See also
  Status Clinical Trial Phase
Recruiting NCT04892745 - Impact of Hemodialysis on Cutaneo-muscular Electrical Impedance
Active, not recruiting NCT03183245 - Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis Phase 3
Completed NCT03365635 - Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C Phase 4
Withdrawn NCT02904343 - Evaluation of Domestic Hemodialysis Machine: A Multi-center Clinical Study N/A
Withdrawn NCT01855334 - L-Arginine and Spironolactone Trial in Dialysis-Dependent ESRD Phase 4
Completed NCT01700465 - Estimating and Predicting Hemodynamic Changes During Hemodialysis N/A
Recruiting NCT01195519 - The Assessment of Quality of Life in Patients With Peritoneal Dialysis and Hemodialysis N/A
Completed NCT00737672 - GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis Phase 3
Completed NCT00527774 - Effect of HCV Infection on Insulin Resistance and Malnutrition-inflammation Complex Syndrome in Regular Hemodialysis Patients N/A
Completed NCT00942253 - Exercise Training in Dialysis Patients With Restless Legs Syndrome (RLS) Phase 2
Completed NCT00224081 - DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin) Phase 4
Completed NCT00850252 - Use of a Lifeline Graft in the A-V Shunt Model Phase 1/Phase 2
Completed NCT00776750 - Influenza Vaccination in Hemodialysis Patients and Renal Transplant Recipients Phase 4
Recruiting NCT06351007 - Educational Program on Dietary Adherence and Nutritional Knowledge in Chronic Kidney Disease Patients (EPAK) N/A
Withdrawn NCT03664141 - Impact of Cannabis Oil on Nutrition in Hemodialysis Patients Study (ICON-HP Study) Phase 3
Completed NCT03909698 - Antibiotic Dosing in Patients on Intermittent Hemodialysis
Recruiting NCT03311321 - Vitamin K to Slow Progression of Cardiovascular Disease Risk in Hemodialysis Patients N/A
Recruiting NCT06098924 - HD Patients' Depression and Happiness
Recruiting NCT03419923 - Three Anticoagulation Strategies for Hemodialysis in Patients at Risk of Hemorrhage N/A
Completed NCT03470727 - The Effect of Citrate Dialysate on Clot Formation and Anemia in Hemodialysis Patients N/A